Methotrexate in psoriasis and psoriatic arthritis
Methotrexate (MTX) is the most commonly prescribed first-line therapy in psoriatic arthritis (PsA) internationally and is also commonly used in the treatment of psoriasis. However, data supporting its use in PsA are limited and significant toxicities can occur. This article summarises a debate at th...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Journal of Rheumatology
2020
|
| Summary: | Methotrexate (MTX) is the most commonly prescribed first-line therapy in psoriatic arthritis (PsA) internationally and is also commonly used in the treatment of psoriasis. However, data supporting its use in PsA are limited and significant toxicities can occur. This article summarises a debate at the 2019 GRAPPA annual meeting that focused on the use of MTX in psoriasis and PsA. Four clinicians and one patient research partner presented clinical study data and the patient experience summarising the efficacy, tolerability and toxicity of MTX for both skin and musculoskeletal manifestations. A live survey of attending GRAPPA members collected data on current and planned future use of MTX across the world. |
|---|